8-K: Cell MedX Corp. Secures $75,000 in Private Placement, Director Participates

Cell MedX Corp. closed a private placement offering, raising $75,000 through the issuance of units, with a company director and spouse participating.

Summary

• Cell MedX Corp. has successfully completed a private placement, raising $75,000.
• The company issued 2,500,000 units at a price of $0.03 per unit.
• Each unit includes one common stock share and one warrant.
• The warrants expire on March 12, 2026.
• Warrants are exercisable at $0.04 per share until September 12, 2024, and at $0.05 per share thereafter.
• A company director and their spouse purchased 1,000,000 units for $30,000 as part of the offering.
• The offering was conducted under Regulation S for non-U.S. persons and Rule 506(b) of Regulation D for U.S. accredited investors.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The company successfully raised capital, but the amount is relatively small and the company is still in an early stage. The director's participation is a positive sign.

Positives

• The company successfully raised $75,000 through a private placement.
• The participation of a director and their spouse demonstrates confidence in the company.
• The structure of the offering includes warrants, which could provide additional capital if exercised.

Risks

• The company's forward-looking statements are subject to risks and uncertainties.
• Actual results may differ materially from anticipated results.
• The securities have not been registered under the U.S. Securities Act and may not be offered or sold within the United States or to U.S. persons unless an exemption from such registration is available.

Future Outlook

The company's future performance is subject to risks and uncertainties, and actual results may vary materially from anticipated results. The company disclaims any obligation to update forward-looking statements.

Management Comments

• David Jeffs, CEO, signed the report on behalf of Cell MedX Corp.

Industry Context

This private placement is a common method for small biotech companies to raise capital for research and development. The company is focused on the anti-aging and wellness market, which is a growing sector.

Comparison to Industry Standards

• Private placements are a typical funding method for early-stage biotech companies like Cell MedX Corp.
• The amount raised, $75,000, is relatively small, suggesting the company is at an early stage of development.
• The use of warrants is a common incentive for investors in private placements, offering potential future upside.
• Comparable companies at a similar stage often raise capital through similar private placements, often with similar terms.

Related Party Transactions

• A director of the company and his spouse participated in the offering, acquiring 1,000,000 units for $30,000.

Stakeholder Impact

• Shareholders may see potential dilution from the issuance of new shares.
• The capital raise provides the company with funds to continue operations and research.
• The company's future success will depend on the development and commercialization of its products.

Next Steps

• The company will continue research and development of its eBalance Technology and eBalance Home System.
• The company will continue to file reports with the SEC.

Key Dates

Keywords

private placement, equity financing, warrants, biotech, Cell MedX Corp, CMXC, Regulation S, Rule 506(b)